Is cardiac hypertrophy a required compensatory mechanism in pressure-overloaded heart?

Journal of Hypertension

Volumn 26, Issue 5, 2008, Pages 857-858

  Samuel, Jane Lise ^a   Swynghedauw, Bernard ^a,b  

^a INSERM   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CYCLOSPORIN; PROPRANOLOL;

APOPTOSIS; CONTROL GROUP; DRUG INHIBITION; EDITORIAL; ENZYME INHIBITION; GENE EXPRESSION; HEART DISEASE; HEART FUNCTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 42049105794     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3282fbf619     Document Type: Editorial

References (22)

1. Alpert NR, Mulieri LA. Increased myothermal economy of isometric force generation in compensated cardiac hypertrophy induced by pulmonary artery constriction in the rabbit. A characterization of heat liberation in normal and hypertrophied right ventricular papillary muscles. Circ Res 1982; 50:491-500.
2. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999; 79:215-262.
3. Lompré AM, Schwartz K, d'Albis A, Lacombe G, Van Thiem N, Swynghedauw B. Myosin isoenzyme redistribution in chronic heart overload. Nature 1979; 282:105-107.
4. Swynghedauw B, Charlemagne D. What is wrong with positive inotropic drugs? Lessons from basic science and clinical trials. Eur Heart J 2002; 4:D43-D49.
5. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987; 60:560-565.
6. Shimoyama M, Hayashi D, Takimoto E, Zou Y, Oka T, Uozumi H, et al. Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. Circulation 1999; 100:2449-2454.
7. Kong Y, Tannous P, Lu G, Berenji K, Rothermel BA, Olson EN, et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 2006; 113:2579-2588.
8. Choukroun G, Hajjar R, Fry S, del Monte F, Haq S, Guerrero JL, et al. Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases. J Clin Invest 1999; 104:391-398.
9. Rogers JH, Tamirisa P, Kovacs A, Weinheimer C, Courtois M, Blumer KJ, et al. RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. J Clin Invest 1999; 104:567-576.
10. Giampetri C, Petrungaro S, Musumeci M, Coluccia P, Antonangeli F, De Desaris P, et al. c-Flip over-expression reduces cardiac hypertrophy in response to pressure-overload. J Hypertens 2008; 26:1008-1016.
11. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006; 7:589-600.
12. Brancaccio M, Fratta L, Notte A, Hirsch E, Poulet R, Guazzone S, et al. Melusin, a muscle-specific integrin beta1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nat Med 2003; 9:68-75.
13. Nakajima A, Kojima Y, Nakayama M, Yagita H, Okumura K, Nakano H. Downregulation of c-FLIP promotes caspase-dependent JNK activation and reactive oxygen species accumulation in tumor cells. Oncogene 2008; 27:76-84.
14. Meeson AP, Radford N, Shelton JM, Mammen PP, DiMaio JM, Hutcheson K, et al. Adaptive mechanisms that preserve cardiac function in mice without myoglobin. Circ Res 2001; 88:713-720.
15. Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J, et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 1998; 281:1690-1693.
16. Meguro T, Hong C, Asai K, Takagi G, McKinsey TA, Olson EN, et al. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res 1999; 84:735-740.
17. Hill JA, Karimi M, Kutschke W, Davisson RL, Zimmerman K, Wang Z, et al. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation 2000; 101:2863-2869.
18. Oie E, Bjornerheim R, Clausen OP, Attramadal H. Cyclosporin A inhibits cardiac hypertrophy and enhances cardiac dysfunction during postinfarction failure in rats. Am J Physiol Heart Circ Physiol 2000; 278:H2115-H2123.
19. Akhter SA, Luttrell LM, Rockman HA, Iaccarino G, Lefkowitz RJ, Koch WJ. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 1998; 280:574-577.
20. Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, Koch WJ, et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 2002; 105:85-92.
21. Marano G, Palazzesi S, Fadda A, Vergari A, Ferrari AU. Attenuation of aortic banding-induced cardiac hypertrophy by propranolol is independent of beta-adrenoceptor blockade. J Hypertens 2002; 20:763-769.
22. Linz W, Scholkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens A 1989; 11:1325-1350.